Park Ha Biological Technology Co., Ltd.BYAH

Park Ha Biological Technology Co., Ltd. (SSE: 688257) is a Shanghai-based micro-cap biological technology outfit whose latest 20-F shows revenue of $2.5 million for the year ending 31 October 2025, a net loss of $24.4 million, and a cash balance of $3.8 million. The filing also reports operating loss of $24.1 million, stockholders’ equity of $4.0 million, and just $85,852 of net cash provided by operating activities. The balance sheet is thin: assets of $6.0 million and liabilities of $2.0 million, with inventory of $75,214 and a rise in inventories of $17,458 over the period. Diluted loss per share is $41.38 on 588,866 weighted diluted shares.

The company describes itself as a provider of biological technology products and services, with a product page listing a single ‘star product’ and a news feed that alternates between 6-K filings and store-opening announcements. Its official site shows a generic product image and a navigation page titled 明星产品 Nav, but neither page contains pricing, customer counts, or evidence of recurring revenue. The filing trail on SEC EDGAR confirms a flurry of 6-K activity in June and July 2026-store openings, membership applications, and global expansion progress-but none of the releases disclose unit economics, contract wins, or timelines for monetisation.

Filings reveal that Park Ha filed a complete membership application on 1 July 2026 and announced a successful store opening on 6 July 2026, while also claiming significant progress in global expansion on 29 June 2026. The SEC submissions JSON for CIK 0001986247 lists these events under 8-K/6-K, but the filings themselves do not quantify revenue impact, customer additions, or cost offsets. The company’s own product rail is therefore promotional imagery and a newsroom; the evidence rail is regulatory disclosure with no audited metrics beyond the 20-F.

What the company does is biological technology research and product commercialisation, but the filings do not state which products are sold, to whom, or at what margin. The absence of segment data, gross margin, R&D capitalisation, or capex breakdown in the 20-F limits insight into the underlying unit economics. The cash balance of $3.8 million and net cash used in operating activities of $85,852 suggest the company is not yet self-funding its operations at scale, and the inventory build of $17,458 implies minimal throughput.

Investors looking for a chart route will find none in the supplied evidence; the renderer may surface TradingView context for SSE: 688257, but the public filings do not supply valuation commentary, valuation multiples, or liquidity metrics. The stock trades on the Shanghai Stock Exchange under ticker 688257 and is classified as a micro-cap biological technology issuer with thin disclosure. The company’s operating history, customer concentration, and product pipeline remain unproven in the evidence set.

The file’s tension sits between the company’s own product and news rails-promotional pages and press-style 6-Ks-and the 20-F, which paints a picture of a cash-burning lab with minimal revenue traction. Until the issuer publishes audited segment data, customer contracts, or product-level margins, the market lacks the granularity to separate signal from noise. The next meaningful catalyst would be a filing that discloses recurring revenue greater than the $2.5 million annual total, a named customer outside China, or a gross margin above the 20-F’s implied sub-1% level.